VWA
TEVA icon

V Wealth Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

V Wealth Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-7,480
Closed -$246K – 648
2017
Q2 		$246K Sell
7,480
-332
-4% -$10.3K 0.12% 159
2017
Q1 		$250K Buy
+7,812
New +$267K 0.15% 148

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

V Wealth Advisors's TEVA Position: Q3 2017 in Review

V Wealth Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 7,480 shares — an estimated $246K sold.

V Wealth Advisors first reported a position in TEVA in Q1 2017 and held it in 2 quarters. The position peaked at $250K in Q1 2017. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • V Wealth Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • V Wealth Advisors sold 7,480 Teva Pharmaceuticals shares in Q3 2017, an estimated $246K.
  • V Wealth Advisors first reported a position in Teva Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • V Wealth Advisors's Teva Pharmaceuticals position peaked at $250K in Q1 2017.
  • 535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on V Wealth Advisors's 13F filing for Q3 2017, filed 12 Oct 2017.